Clinical research highlights with immuno1

• Complete regression of aggressive tumors in animal models
   
• Development of protective immunity — no recurrence even after re-implantation attempts

Our R&D is strengthened through global collaborations:

• Hudson Institute of Medical Research (Monash University) – Validated ImmunoPDT’s unique immune activation mechanism using advanced proteomics.
   
• Prof. Seb Marcuccio – Lead chemist and inventor who synthesized and refined the proprietary compound, ensuring scalability and patentability.
   
• International Advisors – Regulatory, clinical, and operational experts guiding FDA and CE approval pathways

• FDA Phase II/III Trials: Targeting Active Surveillance and Biochemical Relapse patients, with breakthrough designation potential.
   
• Global Expansion: CE marking in Europe, trials in the U.S. and Australia, and treatment centers in developing nations.
   
• Pipeline Growth: Advancing next-generation compounds (“Immuno1 Plus” and “Immuno2”) to expand indications and extend patent life